We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > R-107

News List

Claritas and CMAX Clinical sign agreement for Phase 1 R-107 clinical study pharmaceutical-business-review
April 23, 2021
Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107.
Claritas to expand Covid-19 trial to include sepsis treatment pharmaceutical-technology
April 12, 2021
Claritas Pharmaceuticals is set to expand its development programme for R-107 to include the treatment of Covid-19 related sepsis, which is the leading cause of death in infected patients.
Claritas and Salzman to create nitric oxide-releasing compound for Covid-19 pharmaceutical-technology
March 05, 2021
Claritas Pharmaceuticals (formerly Kalytera Therapeutics) and Salzman Group (SG) have entered a strategic collaboration agreement to accelerate the development of Claritas’ nitric oxide-releasing compound, R-107, for the treatment of Covid-19 ...